AR126649A1 - Formas sólidas de un modulador de hemoglobina - Google Patents

Formas sólidas de un modulador de hemoglobina

Info

Publication number
AR126649A1
AR126649A1 ARP220101301A ARP220101301A AR126649A1 AR 126649 A1 AR126649 A1 AR 126649A1 AR P220101301 A ARP220101301 A AR P220101301A AR P220101301 A ARP220101301 A AR P220101301A AR 126649 A1 AR126649 A1 AR 126649A1
Authority
AR
Argentina
Prior art keywords
compound
formula
crystalline
subject
salt form
Prior art date
Application number
ARP220101301A
Other languages
English (en)
Spanish (es)
Inventor
Stephan D Parent
Travis Lee Houston
Courtney S Johnson
Fang Wang
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of AR126649A1 publication Critical patent/AR126649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP220101301A 2021-05-14 2022-05-13 Formas sólidas de un modulador de hemoglobina AR126649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14

Publications (1)

Publication Number Publication Date
AR126649A1 true AR126649A1 (es) 2023-11-01

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101301A AR126649A1 (es) 2021-05-14 2022-05-13 Formas sólidas de un modulador de hemoglobina

Country Status (13)

Country Link
US (2) US11851424B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337659A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520897A (cg-RX-API-DMAC7.html)
KR (1) KR102968809B1 (cg-RX-API-DMAC7.html)
CN (1) CN117337285A (cg-RX-API-DMAC7.html)
AR (1) AR126649A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022273787B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023021606A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219786A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012156A (cg-RX-API-DMAC7.html)
TW (1) TW202311254A (cg-RX-API-DMAC7.html)
WO (1) WO2022241278A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309517B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP6426694B2 (ja) * 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
AR126648A1 (es) * 2021-05-14 2023-11-01 Global Blood Therapeutics Inc Métodos para hacer un modulador de hemoglobina
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.

Also Published As

Publication number Publication date
JP2024520897A (ja) 2024-05-27
TW202311254A (zh) 2023-03-16
KR20240008356A (ko) 2024-01-18
WO2022241278A1 (en) 2022-11-17
MX2023012156A (es) 2023-10-26
CA3219786A1 (en) 2022-11-17
AU2022273787A1 (en) 2023-10-26
US11851424B2 (en) 2023-12-26
ZA202309517B (en) 2024-06-26
US12473277B2 (en) 2025-11-18
EP4337659A1 (en) 2024-03-20
CN117337285A (zh) 2024-01-02
US20220363674A1 (en) 2022-11-17
KR102968809B1 (ko) 2026-05-26
AU2022273787B2 (en) 2025-04-03
US20240076290A1 (en) 2024-03-07
BR112023021606A2 (pt) 2023-12-19

Similar Documents

Publication Publication Date Title
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
AR120703A1 (es) Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
AR048813A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
AR078318A1 (es) Compuestos carbonatos de anti-biopelicula para su uso en composiciones de cuidado oral
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
JP2005506308A5 (cg-RX-API-DMAC7.html)
BR112018012106A2 (pt) forma cristalina de inibidor de btk quinase e método de preparação da mesma
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
AR128717A1 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
NO954762L (no) Nye tiazolindindioner og legemiddel inneholdende slike
AR091687A1 (es) Formas solidas de inhibidores de fosfodiesterasa tipo 5
DOP2025000064A (es) Proceso para la preparación de un agente de contraste de gadolinio
RU2019102934A (ru) Ингибиторы acc для применения в лечении микобактериальных заболеваний
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
CO2022013595A2 (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
PE20200846A1 (es) Compuesto de heteroarilo con contenido de nitrogeno y su uso farmaceutico
CO6270318A2 (es) Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
JP2016505033A5 (cg-RX-API-DMAC7.html)
CO2021018154A2 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos
CL2025001273A1 (es) Compuesto bicíclico fusionado

Legal Events

Date Code Title Description
FA Abandonment or withdrawal